Medindia

X

Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis

Monday, November 23, 2009 General News J E 4
Advertisement
Goal of Trial Achieved Demonstrating Potentially Less Frequent Administration Using Lower Daily Dose

For more information, please contact:

Karl Cahill, Investor Relations

(858) 531-6100

kcahill@raptorpharma.com

The Ruth Group

Sara Ephraim Pellegrino (investors) / Janine McCargo (media)

(646) 536-7002 / (646) 536-7033

spellegrino@theruthgroup.com / jmccargo@theruthgroup.com

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Raptor Pharmaceutical Corp. Announces Positive Dat...
S
Pharmasset Announces the Continued Enrollment of t...